Strattera (Atomoxetine) Shortage Update: What Patients Need to Know in 2026

If you take atomoxetine for ADHD and have been confused by what's happening with the supply — brand-name Strattera disappearing, a major recall in early 2025, pharmacies saying they're out of stock — this article is for you. Here is a complete timeline of what happened and where things stand in 2026.

Quick Summary: The Current Situation

Brand-name Strattera: Discontinued by Eli Lilly in November 2023. No longer manufactured or available.

Generic atomoxetine: Still widely available from multiple manufacturers including Teva, Aurobindo, Zydus, Hikma, and others.

2025 Glenmark recall: ~1.48 million bottles recalled due to N-nitroso atomoxetine impurity. Affected Glenmark products only; other manufacturers' products were not recalled.

FDA shortage list: Generic atomoxetine is not on the FDA's active drug shortage list as of 2026.

Timeline: How We Got Here

2002: FDA Approves Strattera as First Non-Stimulant ADHD Drug

Eli Lilly received FDA approval for atomoxetine in November 2002, launching it as Strattera. It was the first non-stimulant medication ever approved for ADHD — a significant development for patients who couldn't tolerate or didn't respond to stimulants. At its peak, Strattera generated over $850 million annually in global sales.

2017: Generic Competition Enters the Market

When Strattera's patent expired in May 2017, four manufacturers — Teva, Aurobindo, Apotex, and Glenmark — received FDA approval simultaneously to launch generic atomoxetine. Generic medications typically cost 80–85% less than brand-name equivalents, and patients and insurers quickly shifted to generics. Strattera's brand sales began a steep decline.

November 2023: Eli Lilly Discontinues Brand-Name Strattera

With generic competition dominating the market, Eli Lilly discontinued all strengths of brand-name Strattera in November 2023. This was purely a business decision — not a safety issue. Patients who had been prescribed "Strattera" by brand name were now receiving generic atomoxetine or discovering the brand was unavailable. This transition caused some confusion at pharmacies, particularly for patients who had "Strattera" specifically listed on their prescription.

January 2025: Glenmark Recalls Nearly 1.5 Million Bottles

In January 2025, Glenmark Pharmaceuticals issued a voluntary recall of approximately 1.48 million bottles of generic atomoxetine across all strengths (10 mg through 100 mg). The recall was triggered by the detection of unacceptable levels of N-nitroso atomoxetine — a possible carcinogen — in multiple batches manufactured at Glenmark's facility in Goa, India.

This was significant in scale — 1.48 million bottles is a large volume — and pharmacies that primarily stocked Glenmark's product experienced real supply disruptions. However, the recall did not affect atomoxetine from other manufacturers, and most pharmacies were able to restock from Teva, Aurobindo, Zydus, or other suppliers.

2025–2026: Supply Stabilizes With Multiple Manufacturers

By mid-2025, the market had absorbed the Glenmark recall impact. With at least nine active generic manufacturers producing atomoxetine, the supply base is more resilient than many other generic medications. Prices have also continued to fall — with GoodRx coupons, atomoxetine can cost as little as $15.30 for a 30-day supply of the 40 mg dose, down significantly from a few years ago.

Is There Still a Shortage? What the Data Shows

As of 2026, the FDA does not list generic atomoxetine as an active shortage drug. This is a meaningful distinction from ADHD stimulant medications (Adderall, Ritalin, Vyvanse), which have experienced genuine, prolonged national shortages driven by DEA manufacturing quotas and surging post-pandemic demand.

However, "no national shortage" doesn't mean every pharmacy in your area will have every dose in stock on any given day. Localized stock gaps remain possible, particularly for higher doses (80 mg, 100 mg) at smaller pharmacies or in areas where Glenmark was the dominant supplier.

What To Do If Your Pharmacy Is Out of Stock

The most efficient solution is to contact multiple pharmacies. medfinder calls pharmacies on your behalf and texts you results — saving you the time and frustration of calling each pharmacy yourself. Because atomoxetine is not a controlled substance, your prescription can also be transferred to any pharmacy you choose, and mail-order options like Cost Plus Drugs are available nationwide.

The Bottom Line

The Strattera brand is gone, the 2025 Glenmark recall was disruptive but limited, and as of 2026 the generic atomoxetine supply is generally stable. If you're having trouble finding it locally, check our guide on how to find atomoxetine in stock near you for practical next steps.